Home » Authors » James Etheridge

Articles by James Etheridge

Wittycell licenses Technology For Further Vaccine Research

Jan. 10, 2007

By James Etheridge

$65M Raised By Novexel For Anti-infection, Fungal Research

Jan. 10, 2007

By James Etheridge

Wittycell licenses Technology For Further Vaccine Research

Jan. 10, 2007

By James Etheridge

Report from Europe: Cellectis files IPO prospectus on the Paris Stock Exchange

Jan. 5, 2007

By James Etheridge

Cellectis Files IPO Prospectus On The Paris Stock Exchange

Jan. 3, 2007

By James Etheridge

Cellectis Files IPO Prospectus On The Paris Stock Exchange

Jan. 3, 2007

By James Etheridge

Cerep Aims To Cut Losses And End Its Chemistry Arm

Dec. 27, 2006

By James Etheridge

Cerep Aims To Cut Losses And End Its Chemistry Arm

Dec. 27, 2006

By James Etheridge

IntegraGen Setting Up U.S. Subsidiary For Diagnostics

Dec. 20, 2006

By James Etheridge

BioAlliance Gets Green Light For Phase II/III Transdrug Trial

Dec. 20, 2006

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 12, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
KITE-753, a rapid manufactured CAR T therapy with superior antitumor efficacy and enhanced expansion in vivo
BioWorld Science
In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid...
Keros stock wilts as it halts two dosing arms in hypertension study
BioWorld
After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.